Impel NeuroPharma To Present At The 21st Annual Needham Healthcare Conference

SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Adrian Adams, Chairman and Chief Executive Officer, will present a company overview at the 21st Annual Needham Healthcare Conference being held virtually on Thursday, April 14, 2022 at 1:30 p.m. ET.

A live webcast of the event will be available on the Investors section of the Impel NeuroPharma website at https://investors.impelnp.com/. A replay of the presentation will be available on the website for 90 days.

About Impel NeuroPharmaImpel NeuroPharma, Inc. is a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. In addition to Trudhesa™ (dihydroergotamine mesylate) nasal spray, which is approved in the United States for the acute treatment of migraine with or without aura in adults, Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.

Contact:

Media Relations:Melyssa WeibleElixir Health Public RelationsPhone: (1) 201-723-5805Email: [email protected]

Investor RelationsChristina TartagliaStern Investor RelationsPhone: 212-362-1200Email: [email protected] 

You May Also Be Interested In

• Canadian at our Core: Bruce Power contributing more than $13 billion to Canada's economy over the next 18 months, supporting jobs and business here at home when it matters most
• Avis Budget Group Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Avis Budget Group, Inc. - CAR
• Three Highway Corridors Generated $25.1 Billion in Economic Output